Accessibility Menu
WuXi Biologics (Cayman) logo

WuXi Biologics (Cayman)(OTC) WXXWY

Current Price$9.89
Market Cap$20.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+180%
5 Year-70%
1 Year+30%
1 Month+22%
WuXi Biologics (Cayman) last closing stock price
MetricPriceDate
Last closeUSD 9.892026-07-24
WuXi Biologics (Cayman) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.11%USD 9.502026-07-17
1 month+21.65%USD 8.132026-06-24
3 month+14.59%USD 8.632026-04-24
Year to date+23.63%USD 8.002025-12-31
1 year+30.13%USD 7.602025-07-24
3 year-6.96%USD 10.632023-07-25
5 year-70%USD 32.972021-07-23
Since inception+179.64%USD 3.542017-12-18

WuXi Biologics (Cayman) Financials at a Glance

Market Cap

$20.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥40.25B

Net Income (TTM)

CN¥8.22B

EPS (TTM)

$0.32

P/E Ratio

29.55

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$9.89

Volume

26,251

Open

$9.58

Previous Close

$9.89

Daily Range

$9.58 - $10.19

52-Week Range

$7.27 - $11.21

Estimated Earnings Date

Aug 26, 2026

WXXWY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About WuXi Biologics (Cayman)

WuXi Biologics (Cayman) Inc. is a leading global provider of integrated solutions for biological drug development, encompassing the entire lifecycle from discovery to manufacturing. The company serves clients worldwide, with a strong presence in China, North America, and Europe.

Products and Services
  • Comprehensive biological drug development services
  • Contract development and manufacturing organization (CDMO) for vaccines
  • Advanced testing solutions and biopharmaceutical technology consulting
Growth Outlook
  • Revenue increased to CNY 11.62 billion in Q4 2025
  • Net income rose to CNY 2.52 billion in Q4 2025
  • Strong demand for biologics supports future growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 39.5 billion
  • Operating income margin at 33.14% for Q4 2025
  • Net profit margin of 21.70% in Q4 2025
WuXi Biologics has established itself as a key player in the biotechnology sector, providing essential services that cater to the growing demand for biologics. The company's recent financial performance indicates robust growth, with significant increases in both revenue and net income. The operating income margin reflects efficient management and operational effectiveness, positioning the company favorably for future expansion. With a strong market presence and a diverse range of services, WuXi Biologics is well-positioned to capitalize on the increasing global demand for biopharmaceuticals.
AI Generated • Jul 21, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

13,252

CEO

Zhi Sheng Chen, PhD

Website

www.wuxibiologics.com

Headquarters

Wuxi, JS 214092, CN

WXXWY Financials

Key Financial Metrics (TTM)

Gross Margin

45.98%

Operating Margin

30.47%

Net Income Margin

22.53%

Return on Equity

10.64%

Return on Capital

12.83%

Return on Assets

7.70%

Earnings Yield

3.38%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.07B

Volume

26.25K

Avg. Volume

85.31K

Financials (TTM)

Gross Profit

CN¥17.56B

Operating Income

CN¥11.55B

EBITDA

CN¥14.50B

Operating Cash Flow

CN¥10.07B

Capital Expenditure

-CN¥5.99B

Free Cash Flow

CN¥4.08B

Cash & ST Invst.

CN¥15.75B

Total Debt

CN¥3.11B

WuXi Biologics (Cayman) Performance Analysis

WuXi Biologics (Cayman) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 2,267,494,59642.1%
20232023-12-31CNY 2,404,260,5846.0%
20242024-12-31CNY 2,594,948,5077.9%
20252025-12-31CNY 3,031,254,84316.8%
WuXi Biologics (Cayman) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-300.4%
Q42024-12-3117.8%
Q22025-06-30-1.5%
Q42025-12-3116.7%
WuXi Biologics (Cayman) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.3026.3%
20232023-12-31CNY 0.22-27.3%
20242024-12-31CNY 0.220.0%
20252025-12-31CNY 0.3248.1%
WuXi Biologics (Cayman) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3034.6%
Q42024-12-3122.9%
Q22025-06-3027.9%
Q42025-12-317.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥11.62B

+36.0%

Gross Profit

CN¥5.66B

+73.2%

Gross Margin

48.71%

N/A

Market Cap

$20.49BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.55M

N/A

Employees

13,252

N/A

Net Income

CN¥2.52B

+122.6%

EBITDA

CN¥4.72B

+108.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥15.75B

+40.1%

Total Debt

CN¥3.11B

-31.9%

Accounts Receivable

CN¥8.90B

+43.9%

Inventory

CN¥1.44B

-18.4%

Long Term Debt

CN¥1.85B

-51.7%

Short Term Debt

CN¥1.26B

+71.7%

Return on Assets

7.70%

N/A

Return on Invested Capital

11.98%

N/A

Free Cash Flow

CN¥2.79B

+1174.1%

Operating Cash Flow

CN¥4.59B

+96.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CORTCorcept Therapeutics Incorporated
$95.36-1.34%
RXDXPrometheus Biosciences, Inc.
$199.92+0.09%
NUVLNuvalent, Inc.
$123.96+0.00%
PRAXPraxis Precision Medicines, Inc.
$325.30+0.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About WXXWY

What is the current price of WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) is trading at $9.89 per share.

What is the 52-week range for WuXi Biologics (Cayman)?

Over the past 52 weeks, WuXi Biologics (Cayman) has traded between $7.27 and $11.21.

How much debt does WuXi Biologics (Cayman) have?

As of the most recent reporting period, WuXi Biologics (Cayman) reported total debt of CN¥444.19M.

How much cash does WuXi Biologics (Cayman) have on hand?

WuXi Biologics (Cayman) reported CN¥1.32B in cash and cash equivalents in its most recent financial results.

What is WuXi Biologics (Cayman)’s dividend yield?

WuXi Biologics (Cayman) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services